These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 31085376)
21. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. Newcomer JW CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156 [TBL] [Abstract][Full Text] [Related]
22. Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review. Martínez-Ortega JM; Funes-Godoy S; Díaz-Atienza F; Gutiérrez-Rojas L; Pérez-Costillas L; Gurpegui M Eur Child Adolesc Psychiatry; 2013 Aug; 22(8):457-79. PubMed ID: 23503976 [TBL] [Abstract][Full Text] [Related]
23. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. Saddichha S; Ameen S; Akhtar S J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337 [TBL] [Abstract][Full Text] [Related]
24. Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis. Bak M; Drukker M; Cortenraad S; Vandenberk E; Guloksuz S PLoS One; 2021; 16(2):e0244944. PubMed ID: 33596211 [TBL] [Abstract][Full Text] [Related]
25. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Templeman LA; Reynolds GP; Arranz B; San L Pharmacogenet Genomics; 2005 Apr; 15(4):195-200. PubMed ID: 15864111 [TBL] [Abstract][Full Text] [Related]
26. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study. Smith RC; Maayan L; Wu R; Youssef M; Jing Z; Sershen H; Szabo V; Meyers J; Jin H; Zhao J; Davis JM Psychopharmacology (Berl); 2018 Dec; 235(12):3545-3558. PubMed ID: 30382354 [TBL] [Abstract][Full Text] [Related]
27. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. Alvarez-Jiménez M; González-Blanch C; Crespo-Facorro B; Hetrick S; Rodríguez-Sánchez JM; Pérez-Iglesias R; Vázquez-Barquero JL CNS Drugs; 2008; 22(7):547-62. PubMed ID: 18547125 [TBL] [Abstract][Full Text] [Related]
28. [Weight gain in patients with schizophrenia and schizoaffective disorder induced by the long-term treatment with atypical antipsychotics]. Gorobets LN Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(9):52-6. PubMed ID: 18833173 [TBL] [Abstract][Full Text] [Related]
29. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. Maayan L; Correll CU J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):517-35. PubMed ID: 22166172 [TBL] [Abstract][Full Text] [Related]
30. Effect of treatment on weight gain and metabolic abnormalities in patients with first-episode psychosis. Verma S; Liew A; Subramaniam M; Poon LY Aust N Z J Psychiatry; 2009 Sep; 43(9):812-7. PubMed ID: 19670054 [TBL] [Abstract][Full Text] [Related]
31. Weight gain associated with antipsychotic drugs. Ganguli R J Clin Psychiatry; 1999; 60 Suppl 21():20-4. PubMed ID: 10548138 [TBL] [Abstract][Full Text] [Related]
32. Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. Choi S; DiSilvio B; Unangst J; Fernstrom JD Life Sci; 2007 Sep; 81(12):1024-30. PubMed ID: 17822717 [TBL] [Abstract][Full Text] [Related]
33. Antipsychotic-induced weight gain and therapeutic response: a differential association. Czobor P; Volavka J; Sheitman B; Lindenmayer JP; Citrome L; McEvoy J; Cooper TB; Chakos M; Lieberman JA J Clin Psychopharmacol; 2002 Jun; 22(3):244-51. PubMed ID: 12006893 [TBL] [Abstract][Full Text] [Related]
34. Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. Perez-Iglesias R; Vazquez-Barquero JL; Amado JA; Berja A; Garcia-Unzueta MT; Pelayo-Terán JM; Carrasco-Marín E; Mata I; Crespo-Facorro B J Clin Psychopharmacol; 2008 Jun; 28(3):289-95. PubMed ID: 18480685 [TBL] [Abstract][Full Text] [Related]
35. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis. Siskind D; Hahn M; Correll CU; Fink-Jensen A; Russell AW; Bak N; Broberg BV; Larsen J; Ishøy PL; Vilsbøll T; Knop FK; Kisely S; Ebdrup BH Diabetes Obes Metab; 2019 Feb; 21(2):293-302. PubMed ID: 30187620 [TBL] [Abstract][Full Text] [Related]
36. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs. Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073 [TBL] [Abstract][Full Text] [Related]
37. Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances. Kao AC; Rojnic Kuzman M; Tiwari AK; Zivkovic MV; Chowdhury NI; Medved V; Kekin I; Zai CC; Lieberman JA; Meltzer HY; Bozina T; Bozina N; Kennedy JL; Sertic J; Müller DJ J Psychiatr Res; 2014 Jul; 54():36-42. PubMed ID: 24725652 [TBL] [Abstract][Full Text] [Related]